Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.
The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.
China’s fresh approval of a sublingual form of Simcere's edaravone/dexborneol brain cytoprotective agent for acute ischemic stroke is paving the way for an international Phase III study in this indication.
The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.
With high SVR rates and good safety/tolerability in Phase II, Atea hopes to take its antiviral combo into Phase III. It sees a need for hepatitis C regimens that boost therapeutic compliance.
Zepbound led to greater weight loss versus Wegovy in a Phase III trial, bolstering its position as the superior product in the fast-growing obesity space.
The masked T-cell engager has produced eye-catching results in heavily pre-treated prostate cancer patients, and Janux is aiming to jump ahead of Novartis’s Pluvicto in treatment regimens.
The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.
The motive for the shocking murder of Brian Thompson in New York City was still unknown Wednesday afternoon.
Deal Snapshot: Genentech will pay $40m up front and in the near term, with milestone fees of up to $900m-plus, to use COUR’s tolerogenic nanoparticle treatments in an undisclosed autoimmune disease.
Coherus agreed to sell its biosimilar of Amgen’s Neulasta to Intas in a deal that will clear significant near-term debt and provide funds for a label-expansion strategy for its PD-1 agent Loqtorzi.
Presenting data or announcing a licensing transaction at an appropriately themed conference would normally be expected to be viewed favorably by investors. This is not always the case, however.
Public Company Edition: Biomedtracker data show the amount of money raised in both PIPEs and follow-on offerings surging in 2024. Olema and Cidara raised $250m and $105m, respectively, in recent private placements, while Spyre and Replimune grossed $200m and $140m in FOPOs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Plus deals involving Novartis with Vyriad, Ratio and Schrödinger; Pharmanovia/Lindis, Pulmatrix/Cullgen, Entero/Journey, Roche/Flare and AlloVir/Kalaris.
